Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term "Non-PRMT4 mRNAs with partial complementarity to the PRMT4 shRNA seed region" refers to a collection of messenger RNAs that are unintentionally silenced during experiments using short hairpin RNAs (shRNAs) designed to target Protein Arginine Methyltransferase 4 (PRMT4), also known as CARM1. This phenomenon, known as the RNAi off-target effect, occurs because the 6-8 nucleotide seed sequence of the shRNA possesses partial complementarity to sequences within the 3' untranslated regions (UTRs) of various non-target transcripts (Jackson et al., 2003). When these shRNAs are introduced into cells, they can trigger the degradation or translational repression of these unintended mRNAs via the RNA-induced silencing complex (RISC), mimicking the action of endogenous microRNAs (Birmingham et al., 2006). In cancer research, where PRMT4 is studied for its role in transcriptional co-activation and cell proliferation, such off-target effects can induce phenotypic changes that are incorrectly attributed to PRMT4 knockdown. To ensure experimental validity, researchers often use control strategies like the "C911" mismatch shRNA to distinguish between true PRMT4-dependent effects and these technical artifacts (Buehler et al., 2012). Consequently, these mRNAs represent a significant challenge in target validation and functional genomics rather than being therapeutic targets themselves.
Unintended gene silencing via the RNA interference (RNAi) pathway, where the shRNA seed region (nucleotides 2-8) binds to complementary sequences in the 3' untranslated regions of non-target mRNAs, leading to their degradation or translational repression by the RISC complex.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-Protein arginine methyltransferase 4 messenger RNAs (shRNA off-targets).